Cargando…
A Sponsor’s View on Postmarketing Regulatory Commitments Involving Human Drug Products
Autores principales: | McKinley, Laura, Pressler, Milton L, Hiatt, Mary A., Gregory, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292570/ https://www.ncbi.nlm.nih.gov/pubmed/34251029 http://dx.doi.org/10.1002/cpt.2335 |
Ejemplares similares
-
Employer and Plan Sponsor Views on Pharmacy Reimbursement
por: Stull, Michael, et al.
Publicado: (2020) -
Postmarketing pharmacovigilance: Remdesivir and cardiovascular events
por: Sullivan, John T.
Publicado: (2022) -
Postmarket surveillance of high-risk medical devices needs transparent, comprehensive and independent registries
por: Fraser, Alan G
Publicado: (2020) -
Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
por: Wallach, Joshua D., et al.
Publicado: (2019) -
Understanding the Reporting Practices of CAHPS(®) Sponsors
por: Teleki, Stephanie S., et al.
Publicado: (2007)